Can one gene turn cancer cells back to normal?
Anti-cancer strategies generally involve killing off tumour cells. However, cancer cells may instead be coaxed to turn back into normal tissue simply by reactivating a single gene, according to a study published in the journal Cell.
Researchers found that restoring normal levels of a human colorectal cancer gene in mice stopped tumour growth and re-established normal intestinal function within only four days. Remarkably, tumours were eliminated within two weeks, and signs of cancer were prevented months later. The findings provide proof of principle that restoring the function of a single tumour suppressor gene can cause tumor regression and suggest future avenues for developing effective cancer treatments.
ADVERTISEMENT
Colorectal cancer is the second leading cause of cancer-related death in developed countries, accounting for nearly 700,000 deaths worldwide each year. “Treatment regimes for advanced colorectal cancer involve combination chemotherapies that are toxic and largely ineffective, yet have remained the backbone of therapy over the last decade,” says senior study author Scott Lowe of the Memorial Sloan Kettering Cancer Centre.
Up to 90 per cent of colorectal tumors contain inactivating mutations in a tumour suppressor gene called adenomatous polyposis coli (Apc). Although these mutations are thought to initiate colorectal cancer, it has not been clear whether Apc inactivation also plays a role in tumour growth and survival once cancer has already developed.
“We wanted to know whether correcting the disruption of Apc in established cancers would be enough to stop tumour growth and induce regression,” says first author Lukas Dow of Weill Cornell Medical College. This question has been challenging to address experimentally because attempts to restore function to lost or mutated genes in cancer cells often trigger excess gene activity, causing other problems in normal cells.
To overcome this challenge, Lowe and his team used a genetic technique to precisely and reversibly disrupt Apc activity in a novel mouse model of colorectal cancer. While the vast majority of existing animal models of colorectal cancer develop tumours primarily in the small intestine, the new animal model also developed tumours in the colon, similar to patients. Consistent with previous findings, Apc suppression in the animals activated the Wnt signaling pathway, which is known to control cell proliferation, migration, and survival.
When Apc was reactivated, Wnt signaling returned to normal levels, tumor cells stopped proliferating, and intestinal cells recovered normal function. Tumors regressed and disappeared or reintegrated into normal tissue within two weeks, and there were no signs of cancer relapse over a six-month follow-up period. Moreover, this approach was effective in treating mice with malignant colorectal cancer tumours containing Kras and p53 mutations, which are found in about half of colorectal tumours in humans.
Although Apc reactivation is unlikely to be relevant to other types of cancer, the general experimental approach could have broad implications. “The concept of identifying tumour-specific driving mutations is a major focus of many laboratories around the world,” Dow says. “If we can define which types of mutations and changes are the critical events driving tumour growth, we will be better equipped to identify the most appropriate treatments for individual cancers.”
